2seventy bio, Inc.
TSVT
$0.06
Change (1 day)
$6.40
Year High
$1.54
Year Low
Categories
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
2seventy bio, Inc. (TSVT) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 13.41 M | 181.72 M | 310.13 M | 565.43 M | 237.77 M |
| 2022 | 20.96 M | 199.14 M | 346.2 M | 656.67 M | 300.88 M |
| 2021 | 17 M | 151.8 M | 399.85 M | 759.68 M | 291.56 M |
| 2020 | 10.69 M | 255.21 M | 237.99 M | 312.62 M | 25.1 M |
| 2019 | 7.43 M | 267.15 M | 271.26 M | 314.95 M | 20.84 M |